Is Gyre Therapeutics Inc. (GYRE) overvalued? · rev $53.5M
Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ.
This page asks whether Gyre Therapeutics Inc. (GYRE) looks expensive on cached numbers — not a short thesis.
Latest reported GYRE revenue for 2026-06-30 was $53.5M. Net income was -$32.8M. GYRE currently screens at market cap $589.9M.
GYRE currently screens at market cap $589.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GYRE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GYRE stock page for the full model, not this heading.
Not investment advice.